Previous close | 1.0300 |
Open | 1.0100 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 1.0100 - 1.0100 |
52-week range | 0.5310 - 2.7900 |
Volume | |
Avg. volume | 1,224 |
Market cap | 14.393M |
Beta (5Y monthly) | -4.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1340 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Bloomios, Inc. (the "Company") (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, has acquired Infusionz, a wholly-owned subsidiary of Upexi (NASDAQ: UPXI).
Upexi Inc. (NASDAQ: UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced the sale of select CBD assets to Bloomios, Inc. (OTC: BLMS) for approximately $23.5 million.
Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance solutions, has been engaged by several CBD, nootropic and nutraceuticals brands to develop and produce a new range of private-label consumer health and wellness products.